Dr. Joseph Tucker, CEO of Enveric Biosciences, provided a broader perspective on the challenges highlighted by the FDA’s decision. “The thematic challenges that came to light in the Lykos Adcomm largely focused around two elements, expectation bias and the delivery of the psychological therapy,” Tucker explained. He acknowledged that these issues are difficult to separate from any therapy that induces hallucinations and requires psychotherapy, but he also pointed to the emerging next generation of non-hallucinogenic neuroplastogens as a potential solution. Tucker speculated that these non-hallucinogenic compounds might eventually surpass traditional psychedelics in the field of neuropsychiatric medicine, offering similar therapeutic benefits without the complexities associated with hallucinogenic experiences.
